Intellia Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Intellia Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2023.
  • Intellia Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$136M, a 11% decline year-over-year.
  • Intellia Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$522M, a 12.9% decline year-over-year.
  • Intellia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$481M, a 1.48% decline from 2022.
  • Intellia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$474M, a 77% decline from 2021.
  • Intellia Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$268M, a 99.6% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$481M -$7.01M -1.48% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$474M -$206M -77% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$268M -$134M -99.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$134M +$340M +71.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$474M -$389M -456% Jan 1, 2019 Dec 31, 2019 10-K 2023-02-23
2018 -$85.3M -$17.8M -26.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$67.5M -$35.9M -114% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$31.6M -$19.2M -155% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$12.4M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.